{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:10:27Z","timestamp":1788318627505,"version":"build-2803163510"},"reference-count":88,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,4,7]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Psoriasis and psoriatic arthritis are associated with an increased risk of mental health conditions such as depression and anxiety. People with psoriatic disease (PsD) are also more likely to die by suicide than those without. Mood disorders affect people with PsD in a multitude of ways, such as in effectiveness of care, response to treatment, remission rates, and quality of life. Although the links between PsD and mental health conditions have not been fully elucidated, this review will highlight recent studies investigating shared biologic mechanisms between depression and PsD. Since mental health disorders can be assessed and treated effectively, dermatologists and rheumatologists should be aware of the mental health burden in individuals with PsD to accomplish the following: (1) educate their patients with PsD about this association, (2) screen for mental health conditions on an ongoing basis in their clinical practice, (3) refer their patients with PsD to a mental health professional when needed, and (4) ensure selection of a safe PsD treatment in the setting of comorbid mental health disease. Finally, important treatment considerations for individuals with PsD and depression are reviewed. This topic was presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting.<\/jats:p>","DOI":"10.3899\/jrheum.2024-0362","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T12:18:18Z","timestamp":1721045898000},"page":"43-50","source":"Crossref","is-referenced-by-count":10,"title":["Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5869-5157","authenticated-orcid":false,"given":"Niti","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2743-2263","authenticated-orcid":false,"given":"Elizabeth B.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-2824","authenticated-orcid":false,"given":"Christine","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"2024120403401622000_51.Suppl_2.43.1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"2024120403401622000_51.Suppl_2.43.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2024120403401622000_51.Suppl_2.43.3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1203475420977477","article-title":"Risk of depression in patients with psoriatic disease: a systematic review and meta-analysis","volume":"25","author":"Lukmanji","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"2024120403401622000_51.Suppl_2.43.4","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4103\/0253-7176.168587","article-title":"A cross-sectional study of prevalence and implications of depression and anxiety in psoriasis","volume":"37","author":"Lakshmy","year":"2015","journal-title":"Indian J Psychol Med"},{"key":"2024120403401622000_51.Suppl_2.43.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130797"},{"key":"2024120403401622000_51.Suppl_2.43.6","first-page":"661","article-title":"Medication and health care service utilization related to depressive symptoms in older adults with psoriasis","volume":"3","author":"Kulkarni","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"2024120403401622000_51.Suppl_2.43.7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003412"},{"key":"2024120403401622000_51.Suppl_2.43.8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: a systematic review and meta-analysis","volume":"77","author":"Singh","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024120403401622000_51.Suppl_2.43.9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/kew502","article-title":"Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis","volume":"56","author":"Ogdie","year":"2017","journal-title":"Rheumatology"},{"key":"2024120403401622000_51.Suppl_2.43.10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamadermatol.2015.3605","article-title":"Psoriasis and the risk of depression in the US population: National Health and Nutrition Examination Survey 2009-2012","volume":"152","author":"Cohen","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2024120403401622000_51.Suppl_2.43.11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaclp.2021.12.007","article-title":"Depression and suicidality in patients with psoriasis and the role of psoriatic arthritis: a cross-sectional study in a tertiary setting","volume":"63","author":"Lada","year":"2022","journal-title":"J Acad Consult Liaison Psychiatry"},{"key":"2024120403401622000_51.Suppl_2.43.12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jid.2016.11.032","article-title":"Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-based study","volume":"137","author":"Lewinson","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2024120403401622000_51.Suppl_2.43.13","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.semarthrit.2020.02.001","article-title":"Epidemiology of depression and anxiety in patients with psoriatic arthritis: a systematic review and meta-analysis","volume":"50","author":"Zusman","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2024120403401622000_51.Suppl_2.43.14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3109\/14397595.2015.1136726","article-title":"Incidence rates of suicidal behaviors and treated depression in patients with and without psoriatic arthritis using the Clinical Practice Research Datalink","volume":"26","author":"Hagberg","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2024120403401622000_51.Suppl_2.43.15","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jdv.14175","article-title":"The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis","volume":"31","author":"Wu","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024120403401622000_51.Suppl_2.43.16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jamadermatol.2020.5844","article-title":"Association of patient mental health status with the level of agreement between patient and physician ratings of psoriasis severity","volume":"157","author":"Carr","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2024120403401622000_51.Suppl_2.43.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2014.01.013"},{"key":"2024120403401622000_51.Suppl_2.43.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2015.10.008"},{"key":"2024120403401622000_51.Suppl_2.43.19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40257-017-0279-8","article-title":"Psoriasis, depression, and inflammatory overlap: a review","volume":"18","author":"Patel","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2024120403401622000_51.Suppl_2.43.20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40744-020-00207-6","article-title":"Depression in psoriatic arthritis: dimensional aspects and link with systemic inflammation","volume":"7","author":"Mathew","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024120403401622000_51.Suppl_2.43.21","first-page":"e9708","article-title":"Association between psoriasis and depression: a traditional review","volume":"12","author":"Sahi","year":"2020","journal-title":"Cureus"},{"key":"2024120403401622000_51.Suppl_2.43.22","doi-asserted-by":"crossref","first-page":"adv00609","DOI":"10.2340\/actadv.v101.565","article-title":"Common fundamentals of psoriasis and depression","volume":"101","author":"H\u00f6lsken","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2024120403401622000_51.Suppl_2.43.23","doi-asserted-by":"crossref","first-page":"111065","DOI":"10.1016\/j.biopha.2020.111065","article-title":"Dysregulation of the gut-brain-skin axis and key overlapping inflammatory and immune mechanisms of psoriasis and depression","volume":"137","author":"Wang","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2024120403401622000_51.Suppl_2.43.24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/ijms23020669","article-title":"The brain-skin axis in psoriasis-psychological, psychiatric, hormonal, and dermatological aspects","volume":"23","author":"Marek-Jozefowicz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024120403401622000_51.Suppl_2.43.25","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1007\/s10067-022-06300-1","article-title":"Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients","volume":"41","author":"Tabra","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2024120403401622000_51.Suppl_2.43.26","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/jdv.19192","article-title":"Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation","volume":"37","author":"Mrowietz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024120403401622000_51.Suppl_2.43.27","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.46.6.556"},{"key":"2024120403401622000_51.Suppl_2.43.28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2310\/7750.2009.08068","article-title":"Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis","volume":"13","author":"Chan","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"2024120403401622000_51.Suppl_2.43.29","doi-asserted-by":"crossref","first-page":"adv00020","DOI":"10.2340\/00015555-3375","article-title":"Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk","volume":"100","author":"Kleyn","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2024120403401622000_51.Suppl_2.43.30","doi-asserted-by":"crossref","first-page":"101494","DOI":"10.1016\/j.berh.2020.101494","article-title":"The gut microbiome in psoriasis and psoriatic arthritis","volume":"33","author":"Myers","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024120403401622000_51.Suppl_2.43.31","doi-asserted-by":"crossref","first-page":"100610","DOI":"10.1016\/j.jadr.2023.100610","article-title":"Role of interleukin 17 (IL-17) in the inflammatory hypothesis of depression","volume":"14","author":"Bli\u017aniewska-Kowalska","year":"2023","journal-title":"J Affect Disord Rep"},{"key":"2024120403401622000_51.Suppl_2.43.32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.518837"},{"key":"2024120403401622000_51.Suppl_2.43.33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000492784","article-title":"Depression symptoms predict worse clinical response to etanercept treatment in psoriasis patients","volume":"235","author":"Jin","year":"2019","journal-title":"Dermatology"},{"key":"2024120403401622000_51.Suppl_2.43.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211284"},{"key":"2024120403401622000_51.Suppl_2.43.35","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2016.1128894"},{"key":"2024120403401622000_51.Suppl_2.43.36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10067-019-04734-8","article-title":"Systematic review of mental health comorbidities in psoriatic arthritis","volume":"39","author":"Zhao","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2024120403401622000_51.Suppl_2.43.37","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13306"},{"key":"2024120403401622000_51.Suppl_2.43.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"2024120403401622000_51.Suppl_2.43.39","first-page":"1451","article-title":"Screening for depression in psoriasis patients during a dermatological consultation: a first step towards treatment","volume":"19","author":"Kromer","year":"2021","journal-title":"J Deutsche Derma Gesell"},{"key":"2024120403401622000_51.Suppl_2.43.40","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jaad.2019.01.025","article-title":"Screening for depression and suicidality in psoriasis patients: a survey of US dermatologists","volume":"80","author":"Liang","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024120403401622000_51.Suppl_2.43.41","doi-asserted-by":"crossref","first-page":"2150132720931261","DOI":"10.1177\/2150132720931261","article-title":"Depression screening and measurement-based care in primary care","volume":"11","author":"Siniscalchi","year":"2020","journal-title":"J Prim Care Community Health"},{"key":"2024120403401622000_51.Suppl_2.43.42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"2024120403401622000_51.Suppl_2.43.43","doi-asserted-by":"publisher","DOI":"10.1093\/occmed\/kqu024"},{"key":"2024120403401622000_51.Suppl_2.43.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.12.023"},{"key":"2024120403401622000_51.Suppl_2.43.45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/PRBM.S195181","article-title":"The efficacy of psychological interventions on psoriasis treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Xiao","year":"2019","journal-title":"Psychol Res Behav Manag"},{"key":"2024120403401622000_51.Suppl_2.43.46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","article-title":"Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024120403401622000_51.Suppl_2.43.47","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s40744-021-00377-x","article-title":"Patient-reported outcomes in psoriatic arthritis patients with an inadequate response to biologic disease-modifying antirheumatic drugs: SELECT-PsA 2","volume":"8","author":"Strand","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2024120403401622000_51.Suppl_2.43.48","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1111\/jdv.18475","article-title":"The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2","volume":"36","author":"Kristensen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024120403401622000_51.Suppl_2.43.49","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190507"},{"key":"2024120403401622000_51.Suppl_2.43.50","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22256"},{"key":"2024120403401622000_51.Suppl_2.43.51","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jval.2020.06.007","article-title":"Effects of intravenous golimumab on health-related quality of life in patients with psoriatic arthritis: 24-week results of the GO-VIBRANT trial","volume":"23","author":"Husni","year":"2020","journal-title":"Value Health"},{"key":"2024120403401622000_51.Suppl_2.43.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2024120403401622000_51.Suppl_2.43.53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"2024120403401622000_51.Suppl_2.43.54","doi-asserted-by":"crossref","first-page":"e000808","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2024120403401622000_51.Suppl_2.43.55","doi-asserted-by":"crossref","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2024120403401622000_51.Suppl_2.43.56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13075-018-1769-7","article-title":"Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial","volume":"20","author":"Strand","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024120403401622000_51.Suppl_2.43.57","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091093"},{"key":"2024120403401622000_51.Suppl_2.43.58","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key161"},{"key":"2024120403401622000_51.Suppl_2.43.59","unstructured":"European Medicines Agency . Otezla (apremilast): European public assessment report \u2013 product information. [Internet. Accessed April 12, 2024.] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf"},{"key":"2024120403401622000_51.Suppl_2.43.60","unstructured":"Amgen, Inc. Apremilast (US prescribing information). [Internet. Accessed April 12, 2024.] Available from: https:\/\/www.pi.amgen.com\/united_states\/otezla\/otezla_pi_english.pdf"},{"key":"2024120403401622000_51.Suppl_2.43.61","unstructured":"Bausch Health USA, LLC . Brodalumab (US prescribing information). [Internet. Accessed April 12, 2024.] Available from: https:\/\/www.bauschhealth.com\/Portals\/25\/Pdf\/PI\/Siliq-pi.pdf"},{"key":"2024120403401622000_51.Suppl_2.43.62","unstructured":"European Medicines Agency . Kyntheum (Brodalumab): European public assessment report \u2013 product information. [Internet. Accessed April 12, 2024.] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kyntheum-epar-product-information_en.pdf"},{"key":"2024120403401622000_51.Suppl_2.43.63","unstructured":"European Medicines Agency . Part VI: summary of the risk management plan. Summary of risk management plan for Kyntheum\u00ae (brodalumab). [Internet. Accessed April 12, 2024.] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/kyntheum-epar-risk-management-plan-summary_en.pdf"},{"key":"2024120403401622000_51.Suppl_2.43.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"2024120403401622000_51.Suppl_2.43.65","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"2024120403401622000_51.Suppl_2.43.66","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"key":"2024120403401622000_51.Suppl_2.43.67","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024120403401622000_51.Suppl_2.43.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"2024120403401622000_51.Suppl_2.43.69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017"},{"key":"2024120403401622000_51.Suppl_2.43.70","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"2024120403401622000_51.Suppl_2.43.71","unstructured":"US Food and Drug Administration . Summary Review: BLA 761032 Siliq (Brodalumab), 210-mg single dose prefilled syringe. [Internet. Accessed April 12, 2024.] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761032Orig1s000SumR.pdf"},{"key":"2024120403401622000_51.Suppl_2.43.72","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jdv.15012","article-title":"Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study","volume":"32","author":"Gordon","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024120403401622000_51.Suppl_2.43.73","unstructured":"Clinical review report: guselkumab (Tremfya): (Janssen Inc.). [Internet. Accessed April 12, 2024.] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30480924\/"},{"key":"2024120403401622000_51.Suppl_2.43.74","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/jdv.13918","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials","volume":"31","author":"Tha\u00e7i","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024120403401622000_51.Suppl_2.43.75","unstructured":"Canadian Agency for Drugs and Technologies in Health . Bimekizumab (Bimzelz). [Internet. Accessed April 12, 2024.] Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2022\/SR0698%20Bimzelx%20-%20CADTH%20Final%20Rec%20Final.pdf"},{"key":"2024120403401622000_51.Suppl_2.43.76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13555-022-00861-4","article-title":"Long-term health-related quality of life in patients with plaque psoriasis treated with certolizumab pegol: three-year results from two randomised phase 3 studies (CIMPASI-1 and CIMPASI-2)","volume":"13","author":"Gisondi","year":"2023","journal-title":"Dermatol Ther"},{"key":"2024120403401622000_51.Suppl_2.43.77","unstructured":"US Food and Drug Administration . Multidisciplinary Review and Evaluation: NDA 214958 Sotyktu (deucravacitinib) tablets, 6 mg. [Internet. Accessed April 12, 2024.] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214958Orig1s000MultidisciplineR.pdf"},{"key":"2024120403401622000_51.Suppl_2.43.78","unstructured":"Canadian Agency for Drugs and Technologies in Health . Deucravacitinib (Sotyktu). [Internet. Accessed April 12, 2024.] Available from: https:\/\/canjhealthtechnol.ca\/index.php\/cjht\/article\/view\/SR0756r\/SR0756r"},{"key":"2024120403401622000_51.Suppl_2.43.79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06948.x"},{"key":"2024120403401622000_51.Suppl_2.43.80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67763-X"},{"key":"2024120403401622000_51.Suppl_2.43.81","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mp.2016.167","article-title":"Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions","volume":"23","author":"Kappelmann","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2024120403401622000_51.Suppl_2.43.82","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000479163","article-title":"Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies","volume":"86","author":"Griffiths","year":"2017","journal-title":"Psychother Psychosom"},{"key":"2024120403401622000_51.Suppl_2.43.83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07237.x"},{"key":"2024120403401622000_51.Suppl_2.43.84","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","article-title":"Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials","volume":"156","author":"Augustin","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2024120403401622000_51.Suppl_2.43.85","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2024120403401622000_51.Suppl_2.43.86","unstructured":"Clinical review report: tildrakizumab (Ilumya). [Internet. Accessed February 28, 2024.] Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK583939\/"},{"key":"2024120403401622000_51.Suppl_2.43.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.014"},{"key":"2024120403401622000_51.Suppl_2.43.88","unstructured":"Eli Lilly and Company . A multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of mirikizumab to secukinumab and placebo in patients with moderate to severe plaque psoriasis (OASIS-2). [Internet. Accessed April 12, 2024.] Available from: https:\/\/storage.googleapis.com\/ctgov2-large-docs\/94\/NCT03535194\/Prot_000.pdf"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:41:27Z","timestamp":1733312487000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":88,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.3899\/jrheum.2024-0362"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0362","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}